PUBLIC COMPANY
save$NGNENeurogene Inc.
$NGNENew York, NY, USupdated 13d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
- phase1NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
- phase2Gene Therapy Study for Children With CLN5 Batten Disease
- —A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 26, 26SELLMcMinn Rachel· Chief Executive Officer−$74K↗
- Mar 26, 26SELLCvijic Christine Mikail· President and CFO−$55K↗
- Mar 26, 26SELLJordan Julie· Chief Medical Officer−$18K↗
- Mar 13, 26SELLCobb Stuart· Chief Scientific Officer−$81K↗
- Mar 13, 26SELLCobb Stuart· Chief Scientific Officer−$57K↗
- Mar 13, 26SELLCvijic Christine Mikail· President and CFO−$49K↗
- Mar 13, 26SELLCvijic Christine Mikail· President and CFO−$30K↗
- Mar 13, 26SELLCvijic Christine Mikail· President and CFO−$6K↗
- Mar 13, 26SELLCobb Stuart· Chief Scientific Officer−$3K↗
- Feb 27, 26SELLCvijic Christine Mikail· President and CFO−$121K↗
routine RSU / option mechanics (6)
- Feb 20, 26grantNoonberg Sarah B. · director12,050 sh
- Feb 20, 26grantFreedland Cory S. · director12,050 sh
- Feb 20, 26grantWoods Keith · director12,050 sh
- Feb 20, 26grantCobb Stuart · Chief Scientific Officer16,500 sh
- Feb 20, 26grantJordan Julie · Chief Medical Officer4,900 sh
- Feb 20, 26grantJordan Julie · Chief Medical Officer29,600 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that